RAJAF.US Cordyceps Sunshine Biotech Holdings Co., Ltd.

Consumer Defensive Packaged Foods USA Stocks
9.18 USD
Close of Oct 14, 2026
9.18 9.18
Market cap
USD 1.02B
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is RAJAF.US undervalued?

Graham number

The Graham number of Cordyceps Sunshine Biotech Holdings Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cordyceps Sunshine Biotech Holdings Co., Ltd. fundamental analysis

No fundamental analysis for Cordyceps Sunshine Biotech Holdings Co., Ltd. yet.

Cordyceps Sunshine Biotech Holdings Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cordyceps Sunshine Biotech Holdings Co., Ltd.

TFA Therapeutics, Inc. develops TFA-01 novel nonsteroidal anti-inflammatory drugs for pet medical care. It offers drugs in the areas of canine osteoarthritis, dermatitis, and feline stomatitis. The company serves customers in Taiwan, Japan, Greater China, and United States. TFA Therapeutics, Inc. was formerly known as Cordyceps Sunshine Biotech Holdings Co., Ltd. and changed its name to TFA Therapeutics, Inc. in July 2026. The company was incorporated in 2020 and is based in…

Full company profile